Showing 121-130 of 8647 results for "".
Norlase Launches First Pattern Scanning LIO
https://modernod.com/podcasts/eyewire-news-the-podcast/norlase-launches-first-pattern-scanning-lio/37069/The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchZeiss MEL 90 Approved by FDA
https://modernod.com/podcasts/eyewire-news-the-podcast/zeiss-mel-90-approved-by-fda/37068/Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoicesFirst, At-Home IOP and AMD Monitoring, What Next?
https://modernod.com/articles/significant-findings/first-at-home-iop-and-amd-monitoring-what-next/37818/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatStudy Finds Key Factor in AMD
https://modernod.com/articles/significant-findings/study-finds-key-factor-in-amd/37816/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatPhakic IOL for Presbyopia Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/phakic-iol-for-presbyopia-approved-in-europe/37061/A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoicesLumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
https://modernod.com/podcasts/eyewire-news-the-podcast/lumithera-ceo-discusses-fda-authorization-for-veleda-for-dry-amd/37059/The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.Is Veterinary Eye Tech More Advanced Than Ours?
https://modernod.com/articles/significant-findings/is-veterinary-eye-tech-more-advanced-than-ours/37812/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatGood News for Patients With Dry AMD
https://modernod.com/articles/significant-findings/good-news-for-patients-with-dry-amd/37811/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatLesson Learned: Ask Twice, Consult Once
https://modernod.com/articles/significant-findings/lesson-learned-ask-twice-consult-once/37808/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatB+L Receives FDA Approval for enVista Envy IOL
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-receives-fda-approval-for-envista-envy-iol/37054/Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.